Table 3 Baseline features of inpatients with decompensated cirrhosis in strata by malnutrition and visceral adiposity.

From: Global Leadership Initiative on Malnutrition-defined malnutrition coexisting with visceral adiposity predicted worse long-term all-cause mortality among inpatients with decompensated cirrhosis

 

WNa (n = 145)

WA (n = 19)

MNa (n = 90)

MA (n = 40)

P

Male (%)

53 (36.6)

14 (73.7)

43 (47.8)

32 (80)

<0.001

Age (years)

62 (54, 67)

65 (61, 70)

64 (57,72)

63 (58, 69)

0.019

CTP score

7 (6, 9)

7 (6, 9)

8 (7, 9)

9 (8, 11)

<0.001

MELD-Na score

5.1 (2.6, 10.5)

7.9 (3.5, 12.7)

8.3 (4.1, 13.2)

13.7 (8.8, 19.3)

<0.001

NLR

2.7 (1.6, 4.0)

3.1 (2.0, 4.0)

3.5 (2.2, 4.9)

3.8 (2.6, 8.9)

0.003

PT-INR

1.3 (1.2, 1.4)

1.3 (1.2, 1.4)

1.3 (1.1, 1.5)

1.3 (1.2, 1.5)

0.290

TBIL (μmol/L)

19.3 (13.6, 34.3)

15.4 (12.1, 29.1)

23.8 (14.5, 43.5)

34.9 (17.0, 66.7)

0.011

ALT (U/L)

23 (15, 34)

24 (15, 37)

34 (24, 52)

23 (13, 31)

0.790

AST (U/L)

29 (20, 47)

34 (20, 42)

34 (24, 52)

43 (23, 66)

0.283

Albumin (g/L)

30 (26, 34)

28 (25, 34)

27 (24, 31)

27 (22, 31)

0.001

Cr (μmol/L)

56 (47, 65)

64 (51, 72)

56 (45, 72)

66 (57, 82)

0.002

LDL-C (mmol/L)

2.2 (1.7, 2.6)

1.5 (1.2, 3.3)

2.1 (1.6, 2.5)

2.3 (1.9, 3.1)

0.105

Sodium (mmol/L)

141 (139, 143)

141 (139, 143)

139 (137, 142)

137 (133, 141)

<0.001

WBC (*109/L)

3.2 (2.2, 4.7)

3.4 (2.1, 1.5)

4.0 (2.5, 5.1)

4.5 (3.1, 7.7)

0.020

PLT (*109/L)

82 (59, 123)

70 (33, 87)

85 (61, 130)

91 (54, 149)

0.114

Hemoglobin (g/L)

88 (71, 115)

82 (72, 110)

91 (72, 110)

93 (76, 109)

0.912

SMI (cm2/m2)

45.9 (39.6, 52.4)

49.6 (46.2, 55.1)

41.2 (34.6, 46.1)

40.2 (35.0, 45.4)

<0.001

BMI (kg/m2)

23.9 (21.7, 26.8)

23.7 (22.0, 27.1)

19.2 (17.4, 22.6)

19.1 (17.1, 22.4)

<0.001

Hypertension (%)

40 (27.6)

7 (36.8)

21 (23.3)

17 (42.5)

0.131

CHD (%)

8 (5.5)

0

11 (12.2)

3 (7.5)

0.131

T2DM (%)

34 (23.4)

8 (42.1)

18 (20)

6 (15)

0.134

Complications

Ascites (%)

    

<0.001

 NO

83 (57.2)

8 (42.1)

22 (24.4)

5 (12.5)

 

 Mild

37 (25.5)

8 (42.1)

28 (31.1)

9 (22.5)

 

 Moderate/Bulky

25 (17.3)

3 (15.8)

40 (44.5)

26 (65)

 

GEV (%)

105 (72.4)

14 (73.7)

65 (72.2)

22 (55)

0.173

HE (%)

11 (7.6)

0

5 (5.5)

5 (12.5)

0.372

Infection (%)

14 (9.7)

1 (5.3)

12 (13.3)

11 (27.5)

0.031

Etiology (%)

 Viral

43 (29.7)

5 (26.3)

20 (22.2)

2 (5)

0.006

 Alcoholic

20 (13.8)

8 (42.1)

17 (18.9)

26 (65)

<0.001

 AILD/Cholestasis

49 (33.8)

1 (5.3)

33 (36.7)

3 (7.5)

<0.001

 Others

33 (22.7)

5 (26.3)

20 (22.2)

9 (22.5)

0.974

  1. WNa well-nourished non-visceral adiposity group, WA well-nourished visceral adiposity group, MNa malnourished non-visceral adiposity group, MA malnourished visceral adiposity group, CTP Child-Turcotte-Pugh, MELD-Na model for end-stage liver disease-sodium, NLR neutrophil-to-lymphocyte ratio, PT-INR prothrombin time-international normalized ratio, TBIL total bilirubin, ALT alanine aminotransferase, AST aspartate aminotransferase, Cr creatinine, LDL-C low-density lipoprotein cholesterol, WBC white blood cell count, PLT platelet count, SMI skeletal muscle index, BMI body mass index, CHD coronary heart disease, T2DM type 2 diabetes, GEV gastroesophageal variceal hemorrhage, HE hepatic encephalopathy, AILD autoimmune liver disease.
Back to article page